ASH 2015 - Leukemia

Multikinase Inhibitor Midostaurin in Newly Diagnosed AML Patients with FLT3 Mutations: Results of the CALGB 10603/RATIFY Trial

Conference Correspondent - ASH 2015 - Leukemia

Midostaurin, a multitargeted small-molecule FMS-like tyrosine kinase 3 receptor (FLT3) inhibitor, has demonstrated single-agent activity in patients with acute myeloid leukemia (AML) harboring activating both internal tandem duplication (ITD) and tyrosine kinase domain (TKD) FLT3 mutations.1 The randomized phase 3 [ Read More ]

Effect of Nilotinib Treatment Duration on Treatment-Free Remission in CP-CML Patients Previously Treated with Imatinib: Interim Results of the ENESTPath Phase 3 Trial

Conference Correspondent - ASH 2015 - Leukemia

In contrast to current recommendations to continue tyrosine kinase inhibitor therapy indefinitely, emerging evidence indicates that patients with sustained molecular responses (MRs) on imatinib therapy may achieve deep MRs and durable treatment-free remission (TFR) with nilotinib in patients with chronic-phase [ Read More ]

Blinatumomab Treatment in Adult Patients with Relapsed/Refractory B-Precursor ALL Post-Allogeneic Hematopoietic Stem-Cell Transplantation

Conference Correspondent - ASH 2015 - Leukemia

The prognosis of adult patients with relapsed and/or refractory acute lymphoblastic leukemia (ALL) who have had prior allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is poor, underscoring the need for novel therapeutic options. Blinatumomab is a bispecific T-cell engaging (BiTE®) CD19-directed antibody [ Read More ]

CD19-Targeted 19-28z CAR-Modified T-Cells in Adult Patients with Relapsed/Refractory B-Cell ALL: Impact of MRD-Negative CR and Allogeneic Stem-Cell Transplant on Outcomes

Conference Correspondent - ASH 2015 - Leukemia

Targeted immunotherapy with T-cells expressing a CD19-targeting 19-28z chimeric antigen receptor (CAR) has demonstrated high antileukemia activity in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Park and colleagues reported the long-term safety and antitumor activity of 19-28z [ Read More ]